BioCentury | Nov 13, 2020
Translation in Brief

Roche and Immune-Onc mAb data; plus Capricor’s exosome-based COVID-19 vaccine induces cellular immunity, and more

...Immunotherapy of Cancer (SITC) meeting showing its LILRB2...
...G3IL-2 – Interleukin-2 IL-4 (BSF1) – Interleukin-4 LILRB2 (LIR2) – Leukocyte immunoglobulin-like receptor subfamily B member 2 SARS-CoV-2...
...Immunotec Ltd. Stanford University Shattuck Labs Inc. ImCheck Therapeutics S.A.S. Interleukin-2 (IL-2) Leukocyte immunoglobulin-like receptor subfamily B member 2 (LILRB2) (LIR2) SARS-CoV-2...
BioCentury | Oct 3, 2020
Management Tracks

Li to guide Merck’s next wave of cancer therapies launched by Perlmutter

...Editor Lauren Martz contributed to this report.TARGETSILT4 (LILRB2...
BioCentury | Sep 26, 2020
Product Development

Merck’s myeloid data add support for the emerging target class

...I GIDO  (INDO) – Indoleamine 2,3- dioxygenaseILT4 (LILRB2...
...domain protein 1 Lauren Martz Merck & Co. Inc. Genentech Inc. Leukocyte immunoglobulin-like receptor subfamily B member 2 (LILRB2) (LIR2) T...
BioCentury | Sep 1, 2020
Deals

Gilead deal clears path for Jounce to advance immuno-oncology programs

...latter molecule, an antibody targeting myeloid surface receptor LILRB2...
...protein 4ICOS - Inducible T cell co-stimulatorLILRB2 (LIR2...
BioCentury | Jun 6, 2020
Product Development

June 5 Quick Takes: Merck, Tetraphase-Melinta, Apeiron, Neurasic, Jounce, Genmab-J&J

...Co. (NYSE:BMY) has returned to Jounce Therapeutics Inc. (NASDAQ:JNCE) exclusive worldwide rights to JTX-8064, an anti-LILRB2...
...Secures J&J’s Lead in MM” ). Targets ACE2 - Angiotensin-converting enzyme 2 LILRB2 (LIR2) - Leukocyte immunoglobulin-like receptor subfamily B member 2 BioCentury...
...Inc. McGill University Jounce Therapeutics Inc. Bristol Myers Squibb Co. Genmab A/S Merck & Co. Inc. UCB S.A. Apeiron Biologics AG Engage Therapeutics Inc. Leukocyte immunoglobulin-like receptor subfamily B member 2 (LILRB2) (LIR2) Angiotensin-converting...
BioCentury | Jul 24, 2019
Company News

New flexibility and a new Celgene deal for Jounce

...Celgene Corp. (NASDAQ:CELG) gained exclusive, worldwide rights to JTX-8064, an antibody targeting myeloid surface receptor LILRB2...
...Cytotoxic T-lymphocyte associated protein 4; ICOS - Inducible T cell co-stimulator; LILRB2 (LIR2) - Leukocyte immunoglobulin-like receptor subfamily B member 2...
...death 1 Elizabeth S. Eaton, Staff Writer JTX-4014 JTX-8064 vopratelimab (JTX-2011) Bristol-Myers Squibb Co. Celgene Corp. Jounce Therapeutics Inc. Inducible T cell co-stimulator (ICOS) Leukocyte immunoglobulin-like receptor subfamily B member 2 (LILRB2) (LIR2)...
BioCentury | Mar 29, 2019
Targets & Mechanisms

AACR moves in a myeloid direction

...abstract from Jounce Therapeutics Inc. shows JTX-8064, a preclinical antibody targeting the myeloid surface receptor LILRB2...
...High mobility group AT-hook 1 IRAK3 - Interleukin-1 receptor-associated kinase 3 LILRB2 (LIR2) - Leukocyte immunoglobulin-like receptor subfamily B member 2...
BioCentury | Oct 17, 2018
Preclinical News

Immune-Onc, University of Texas discover new AML target

A study published Wednesday in Nature revealed a checkpoint inhibitor target for acute myelogenous leukemia, adding a new mechanism of action for an indication that, until recently, has been a new drug wasteland. Immune-Onc Therapeutics...
BioCentury | Mar 2, 2018
Product R&D

Sigma for synapses

...oligomer’s receptor isn’t known, but evidence in the literature suggests its protein complex could contain LILRB2...
...induces a conformational change in the oligomer receptor complex. Source: Cognition Therapeutics LILRB2 (LIR2) - Leukocyte immunoglobulin-like receptor subfamily B member 2...
...Louis, St. Louis, Mo. Yale University, New Haven, Conn. Targets and Compounds LILRB2 (LIR2) - Leukocyte immunoglobulin-like receptor subfamily B member 2...
BioCentury | Jan 4, 2018
Translation in Brief

New Therapeutic Targets and Biomarkers: December 2017

New Therapeutic Targets and Biomarkers: December 2017 Select top therapeutic targets and biomarkers covered by BioCentury or added to the BCIQ database during December 2017. Therapeutic targets are defined as any protein, gene or other...
Items per page:
1 - 10 of 18